Eric Schoen, Chief Financial Officer of Filana Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing an open-market purchase of common stock on November 16, 2026.

Key Highlights

  • Reporting person: Eric Schoen, identified as Chief Financial Officer of Filana Therapeutics, Inc.
  • Transaction: Purchase (transaction code P) of 20,000 shares of common stock on November 16, 2026.
  • Price paid: $0.42 per share, according to the filing.
  • Resulting ownership: 31,500 shares of common stock beneficially owned directly following the reported transaction.
  • Exchange and ticker: The issuer is listed as NASDAQ:FLNA in the filing.

Schoen's November 2026 Purchase of Filana Therapeutics Common Stock

According to the Form 4 filed with the SEC on November 18, 2026, Eric Schoen, the Chief Financial Officer of Filana Therapeutics, Inc. (NASDAQ:FLNA), reported a purchase of 20,000 shares of the company's common stock. The transaction was executed on November 16, 2026, at a price of $0.42 per share. The filing records the transaction under code "P," indicating an open-market purchase. The ownership form is listed as direct.

Following the reported transaction, the filing states that Schoen beneficially owns 31,500 shares of Filana Therapeutics common stock directly. No derivative securities transactions were reported in Table II of the filing. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1 trading plan, as the corresponding checkbox on the form was not checked.

The Form 4 was signed by Eric J. Schoen and dated November 18, 2026. Filana Therapeutics, Inc. is headquartered at 6801 N Capital of Texas Hwy, Bldg 1, Suite 300, Austin, Texas 78731, according to the address provided in the filing.

What Was Disclosed

The filing disclosed a direct open-market purchase of 20,000 shares of Filana Therapeutics common stock by CFO Eric Schoen at $0.42 per share on November 16, 2026, resulting in total direct beneficial ownership of 31,500 shares.